Daily funding roundup - September 28th, 2018

SoloLearn raised $5.6M; DAILYLOOK raised $8M; Broadly raised $10M; Covr raised $10M

SoloLearn: SoloLearnlets you learn and practice a skill of your choice anytime anywhere for free. It consists of very short videos and interactive checkpoints and practice sessions. The practice is real, i.e. programming students write real-life code and future photographers adjust camera settings in the app. SoloLearn has raised $5.6 million in Series A funding. Read more »

DAILYLOOK: DAILYLOOK is the premium personal styling experience that provides the latest looks tailored to your lifestyle - saving you time and effort. They make shopping simple, by curating looks you love based on your body shape, preferences, and lifestyle. DAILYLOOK has raised $8 million in Series A funding. Read more »

Broadly: Broadly helps busy small business owners stay connected with their customers through web chat and review management. Broadly has raised $10 million in Series B funding. Read more »

Covr Financial Technologies: Covr is a digital life insurance platform that makes it easy to protect what matters most: you and your family. Covr partners with financial institutions that share the belief that life insurance should be simple and transparent and part of a total financial plan. Covr has raised $10 million in Series A funding. Read more »

Capella Space: Capella Space is a data company that provides persistent and reliable information from space with its constellation of (very small) satellites. Capella's satellites can see through the clouds and at night time making them immune to bad weather or light conditions. Capella Space has raised $19 million in Series B funding. Read more »

Guardhat: Guardhat is a multi-product, feature-packed intelligent safety system that integrates cutting edge wearable technology and advanced proprietary software. Guardhat has raised $20 million in Series A funding. Read more »

Akebia Therapeutics: Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme.  Akebia Therapeutics has raised $30 million in Series A funding co-led by F-Prime Capital Partners and Atlas Venture. Read more »